Elicio Therapeutics
ELTX
21 hedge funds and large institutions have $11.2M invested in Elicio Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
14% more capital invested
Capital invested by funds: $9.8M → $11.2M (+$1.38M)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.97% less ownership
Funds ownership: 10.04% → 9.07% (-0.97%)
13% less funds holding
Funds holding: 24 → 21 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$827K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$270K |
| 3 |
MFA
Mayflower Financial Advisors
Boston,
Massachusetts
|
+$62.2K |
| 4 |
P
&Partners
Nashville,
Tennessee
|
+$62.2K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$37.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.13M |
| 2 |
Millennium Management
New York
|
-$322K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$225K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$187K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$94.4K |
ELTX Hedge Fund Activity: Q2 2025 in Review
21 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2025, worth a combined $11.2M — up 14% from $9.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELTX and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $827K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $1.13M sold.
- 21 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2025, down from 24 in Q1 2025.
- Funds reported $11.2M of Elicio Therapeutics stock for Q2 2025, up 14% quarter-over-quarter.
- 3 funds opened new Elicio Therapeutics positions in Q2 2025 and 6 closed out, a net change of -3 holders.
- The largest Elicio Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $827K added.
- The largest Elicio Therapeutics seller in Q2 2025 was Hudson Bay Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2025.